Drug Development

ALTU-135 well tolerated in cystic fibrosis patients with pancreatic insufficiency

Published in Drug Week, November 25th, 2005

Altus Pharmaceuticals, Inc., presented results from its phase II clinical trial of ALTU-135 (TheraCLEC) in cystic fibrosis (CF) patients with malabsorption due to pancreatic insufficiency at the North American Cystic Fibrosis Conference in Baltimore, Maryland.

In the study, when delivered at a fixed dose, ALTU-135 was well-tolerated and achieved statistically significant improvements in the absorption of fat and protein as well as an overall improvement in the absorption of carbohydrates, all of which are essential for proper nutrition and growth.

The phase II study enrolled 125 patients who were treated at 26 CF centers in the U.S., and the company...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-11-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry